Skip to main content

Table 4 Skin and soft tissue infections (SSTI) caused by S. aureus—estimated days of therapy per 100 bed days: one year prior to and one year after implementing selective reporting

From: Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting

Antibiotics Prior to implementing elective reporting
n = 85, BD = 729 		After implementing selective reporting
n = 88, BD = 562 		DOT per 100 BD after vs. prior#
pat/ DOT/DOT per 100 BD (95%-CI)* pat/ DOT/DOT per 100 BD (95%-CI)* IRR (95%-CI) p
Selectively reported antibiotics
Flucloxacillin iv + Cefazolin iv 9 / 61 / 8.4 (2.4; 14.4) 18 / 101 / 18.0 (10.3; 25.6) 2.15 (0.93; 4.95) 0.073
Cefalexin po 3 / 10 / 1.4 (−0.3; 3.1) 17 / 53 / 9.4 (4.5; 14.4) 6.87 (1.81; 26.15) 0.005
Trimethoprim-sulfamethoxazole 2 / 3 / 0.4 (−0.2; 1.0) 0 0 –
Clindamycin iv/po 12 / 73 / 10.0 (3.3; 16.7) 15 / 61 / 10.9 (4.6; 17.1) 1.08 (0.45; 2.61) 0.857
Sum of above named selectively reported antibiotics 21 / 147 / 20.2 (11.0; 29.3) 36 / 215 / 38.3 (27.2; 49.3) 1.90 (1.11; 3.25) 0.020
Combination therapy only
Gentamicin + Tobramycin + Amikacin iv 0 / 0 / 0 (0.0; 0.0) 1 / 4 / 0.7 (−0.7; 2.1) – –
Rifampin iv/po 1 / 3 / 0.4 (-0.4; 1.2) 1 / 4 / 0.7 (−0.7; 2.1) 1.73 (0.11; 28.23) –
Fosfomycin iv 1 / 2 / 0.3 (−0.3; 0.8) 0 0 –
No longer reported antibiotics
Penicillin G + Ampicillin/Amoxicillin iv 2 / 10 / 1.4 (−0.7; 3.4) 4 / 14 / 2.5 (−0.0; 5.0) 1.82 (0.30; 11.14) –
Ampicillin-sulbactam + Amoxicillin-clavunate iv/po 42 / 173 / 23.7 (14.7; 32.7) 56 / 192 / 34.2 (23.7; 44.7) 1.44 (0.88; 2.35) 0.143
Piperacillin-tazobactam 5 / 13 / 1.8 (−0.2; 3.8) 7 / 37 / 6.6 (1.6; 11.5) 3.69 (0.97; 14.03) 0.055
Cefuroxime iv/po 24 / 95 / 13.0 (7.2; 18.9) 14 / 57 / 10.1 (3.7; 16.6) 0.78 (0.36; 1.69) 0.527
Ceftriaxone iv + Ceftazidime iv + Cefpodoxime po 2 / 27 / 3.7 (-2.2; 9.6) 0 0 –
Imipenem-cilastatin iv + Meropenem iv 4 / 27 / 3.7 (−0.3; 7.7) 0 0 –
Ciprofloxacin + Levofloxacin + Moxifloxacin iv/po 8 / 27 / 3.7 (0.7; 6.7) 2 / 10 / 1.8 (−0.8; 4.3) 0.48 (0.09; 2.52) 0.385
Sum of above named no longer reported antibiotics 75 / 372 / 51.0 (40.8; 61.2) 76 / 310 / 55.2 (45.7; 64.6) 1.08 (0.83; 1.41) 0.562
  1. *Pat/ DOT/DOT per 100 BD (95%-CI): number of patients, days of therapy (DOT), days of therapy per 100 bed days (BD) with 95%-confidence interval estimated by Poisson regression;
  2. #Poisson regression, incidence rate ratio (IRR) with 95%-confidence interval (CI) and p-value (p), p-values < 0.05 in bold. In case of less than 5 patients in both periods no statistical test was performed
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us